Disc medicine presents positive updated results from phase 1b trial in patients with myelofibrosis (mf) and anemia in an oral presentation at the 66th american society of hematology (ash) annual meeting

Watertown, mass., dec. 08, 2024 (globe newswire) -- disc medicine, inc. (nasdaq:iron), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive updated results from a phase 1b trial of disc-0974 in patients with myelofibrosis (mf) and anemia. the data, presented in an oral session at the 2024 american society of hematology (ash) annual meeting in san diego, ca, demonstrated that treatment with disc-0974 results in substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types.
MF Ratings Summary
MF Quant Ranking